Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.51 |
| ▸ | BACE1 | P56817 | 11/20 | 0.51 |
| ▸ | BCHE | P06276 | 9/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1373877 | 0.79 | GRIN2B (0.50) | ACHEBACE1BCHEGRIN2BFYN | |
| SCHEMBL2301167 | 0.77 | GRIN2B (0.56) | ACHEBACE1BCHEGRIN2BFYN | |
| SCHEMBL663239 | 0.74 | GRIN2B (0.74) | ACHEBACE1BCHEGRIN2BFYN | |
| SCHEMBL24928272 | 0.74 | ACHE (0.54) | ACHEBACE1BCHEGRIN2BFYN | |
| SCHEMBL9965855 | 0.74 | ACHE (0.54) | ACHEBACE1BCHEGRIN2BFYN | |
| SCHEMBL17320169 | 0.74 | ACHE (0.58) | ACHEBACE1BCHEGRIN2BFYN | |
| Hydrochloric Acid SCHEMBL2550113 | 0.72 | MEN1 (0.78) | ACHEBACE1BCHEGRIN2BFYN | |
| SCHEMBL2092320 | 0.71 | GRIN2B (0.54) | ACHEBACE1BCHEGRIN2BFYN | |
| SCHEMBL18471685 | 0.71 | ACHE (0.51) | ACHEBACE1BCHEGRIN2BFYN | |
| SCHEMBL4173336 | 0.71 | GRIN2B (0.69) | ACHEBACE1BCHEGRIN2BFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2346821-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | Exelixis, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010045580-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS | EXELIXIS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | ACHE 4876/4885BACE1 2175/4885BCHE 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.